[Regression of functional cysts: high dosage ovulation inhibitor and gestagen therapy has no added effect]
- PMID: 7557205
- DOI: 10.1055/s-2007-1022807
[Regression of functional cysts: high dosage ovulation inhibitor and gestagen therapy has no added effect]
Abstract
To investigate the need for hormonal treatment in patients with functional ovarian cysts (FOC), the efficacy of this treatment was evaluated in a retrospective and also in a randomised prospective study. By retrospective analyses the resolution of FOC with a mean diameter larger than 2.0 cm at the beginning of a cycle was determined in 113 patients (31.6 +/- 4.6 years). Fifty-seven women received an oral contraceptive (ethinylestradiol 50 micrograms/d for 7 days, ethinylestradiol 50 micrograms and desogestrel 125 micrograms/d for 15 days), the others had no therapy. In a second study 59 patients (32.3 +/- 4.6 years) were randomised to receive a combination of ethinylestradiol 50 micrograms and levonorgestrel 250 micrograms/d for 21 days (Group 1, n = 24), or lynestrenol 10 mg/d continuously (Group 2, n = 14) or a third group (Group 3, n = 21) without treatment. In both studies no differences were found between those patients who had hormonal treatment and those who had not. The prospective study revealed that spontaneously appearing FOC and FOC evolving after ovulation induction during the cycle prior to study enrolment, resolved equally well within 12 weeks independent of contraceptive or gestagen treatment. FOC persisted in only one woman (group 2) who had a surgically proven endometrioma. In conclusion, hormonal treatment does not produce regression of FOC in women of reproductive age.
Similar articles
-
Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.Prescrire Int. 2006 Apr;15(82):50-3. Prescrire Int. 2006. PMID: 16604729
-
Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.Arzneimittelforschung. 1985;35(3):630-3. Arzneimittelforschung. 1985. PMID: 3158320 Clinical Trial.
-
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.Thromb Haemost. 2002 Feb;87(2):199-205. Thromb Haemost. 2002. PMID: 11859850 Clinical Trial.
-
[Medical and surgical treatment of functional ovarian cysts].J Gynecol Obstet Biol Reprod (Paris). 2001 Nov;30(1 Suppl):S41-52. J Gynecol Obstet Biol Reprod (Paris). 2001. PMID: 11917375 Review. French.
-
[Low dose oral contraceptives: 30 microg are still used?].Minerva Ginecol. 2009 Oct;61(5):453-8. Minerva Ginecol. 2009. PMID: 19749677 Review. Italian.
Cited by
-
Oral contraceptives for functional ovarian cysts.Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD006134. doi: 10.1002/14651858.CD006134.pub5. Cochrane Database Syst Rev. 2014. PMID: 24782304 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical